[Form 4] Albemarle Corporation Insider Trading Activity

Rhea-AI Filing Summary

Albemarle Corporation (ALB) – Form 4 Insider Transaction

Director James J. O’Brien reported two share acquisitions dated 1 July 2025:

• 2,725 common shares granted as the annual installment of non-employee director compensation under the company’s 2023 Stock Compensation and Deferral Election Plan. These shares are scheduled to vest on 1 July 2026.
• 37 common shares issued in lieu of cash dividends that accrued on a prior award granted 1 July 2024 and fully vested on 1 July 2025.

Both transactions were reported with a $0.00 acquisition price, indicating they are equity compensation rather than open-market purchases. Following the two grants, O’Brien’s direct beneficial ownership increased to 8,085 common shares.

No derivative securities were reported and no dispositions occurred. An Exhibit 24 Power of Attorney was filed to authorize the attorney-in-fact signature.

The filing is routine, reflecting scheduled director equity awards rather than discretionary insider buying or selling.

Insights

Securities Analyst

TL;DR: Routine stock grant; neutral signal.

The reported acquisitions stem from Albemarle’s standard non-employee director compensation plan. Because the shares were issued at no cost and pursuant to a pre-existing program, they do not reflect discretionary insider sentiment. The incremental increase to 8,085 shares is immaterial relative to Albemarle’s roughly 117 million shares outstanding. Therefore, the filing is operationally neutral and should not influence valuation or trading outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OBRIEN JAMES J /KY

(Last) (First) (Middle)

ALBEMARLE CORPORATION

4250 CONGRESS STREET, SUITE 900

(Street)

CHARLOTTE NC 28209

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALBEMARLE CORP [ ALB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		A		2,725(1)	A	$0	8,048	D
Common Stock	07/01/2025		A		37(2)	A	$0	8,085	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares represent an annual installment of non-employee director stock compensation pursuant to the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors of Albemarle Corporation (the "2023 Directors Plan"). Shares to vest on July 1, 2026.

2. Represents dividends accrued on shares underlying an award granted on July 1, 2024, that vested in full on July 1, 2025, which the Issuer elected to settle in shares of common stock under the 2023 Directors Plan.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Rebekah Richards, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Albemarle (ALB) shares did Director James J. O’Brien acquire on 1 July 2025?

He received 2,725 shares as annual director compensation and 37 dividend shares, totaling 2,762 shares.

What is James J. O’Brien’s total Albemarle share ownership after the Form 4 filing?

His direct beneficial ownership increased to 8,085 common shares.

Were the shares purchased on the open market?

No. All shares were issued at $0.00 under the company’s 2023 Directors Plan, not bought in the market.

When will the 2,725 compensation shares vest?

They are scheduled to vest on 1 July 2026.

Did the filing report any derivative securities or sales by the director?

No derivative securities were reported, and no shares were sold in this filing.